Present and future challenges in Type 2 diabetes

Drug Discovery World

Volumn 12, Issue 3, 2011, Pages 9-15

  Millatt, Lesley J ^b   Hanf, Rémy ^a   Hum, Dean W ^b  

^a Drug Development and Translational Research at Genfit   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; APD 597; BI 10773; DAPAGLIFLOZIN; GFT 505; INCB 13739; INT 777; LX 4211; MBX 2982; MK 0916; SRT 2104; UNCLASSIFIED DRUG;

CAUSE OF DEATH; DRUG MECHANISM; DRUG RESEARCH; EPIDEMIC; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 79960978756     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Grundy, SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov, 2006. 5(4): p. 295-309.
2. Haffner, SM et al., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998. 339(4): p. 229-34.
3. Meier, M and Hummel, M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag, 2009. 5: p. 859-71.
4. Best, JH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide I (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care, 2011. 34(1): p. 90-5.
5. Hermanowski-Vosatka, A et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med, 2005. 202(4): p. 517-27.
6. Rosenstock, J et al. The 11-beta-hydroxysteroid dehydrogenase type I inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care, 2010. 33(7): p. 1516-22.
7. Feig, PU et al. Effects of an 11beta-hydroxysteroid dehydrogenase type I inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab, 2011. 13(6): p. 498-504.
8. Chu, ZL et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology, 2007. 148(6): p. 2601-9.
9. Semple, G et al. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett, 2011. 21 (10): p. 3134-41.
10. Overton, HA et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab, 2006. 3(3): p. 167-75.
11. Katsuma, S, Hirasawa, A and Tsujimoto, G. Bile acids promote glucagon-like peptide-I secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun, 2005. 329(1): p. 386-90.
12. Watanabe, M et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 2006. 439(7075): p. 484-9.
13. Keitel, V et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun, 2008. 372(1): p. 78-84.
14. Keitel, V et al.The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology, 2007. 45(3): p. 695-704.
15. Thomas, C et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab, 2009. 10(3): p. 167-77.
16. Milne, JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007. 450(7170): p. 712-6.
17. Zhang, QJ et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res, 2008. 80(2): p. 191-9.
18. Hsu, CP et al. Silent information regulator I protects the heart from ischemia/reperfusion. Circulation, 2010. 122(21): p. 2170-82.
19. Li, L et al. SIRT1 Acts as a Modulator of Neointima Formation Following Vascular Injury in Mice. Circ Res, 2011. 108(10): p. 1180-9.
20. Komoroski, B et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther, 2009. 85(5): p. 513-9.
21. Aires, I and Calado, J. BI10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs, 2010. 11 (10): p. 1182-90.
22. Vemula, S et al. A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther, 2009. 328(2): p. 487-95.
23. Edfalk, S, Steneberg, P and Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes, 2008. 57(9): p. 2280-7.
24. Nagasumi, K et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes, 2009. 58(5): p. 1067-76.
25. Tan, CP et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes, 2008. 57(8): p. 2211-9.
26. Zhang, X et al. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother, 2010. 64(9): p. 647-51.
27. Dormandy, JA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005. 366(9493): p. 1279-89.
28. Sarafidis, PA and Bakris, GL Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006. 70(7): p. 1223-33.
29. Sanyal, AJ et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med, 2010. 362(18): p. 1675-85.
30. Lecka-Czernik, B. Aleglitazar, a dual PPARalpha and PPARgamma agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs, 2010. 13(11): p. 793-801.
31. Coll, T et al. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr Mol Pharmacol, 2009. 2(1): p. 46-55.
32. Keech, A et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005. 366(9500): p. 1849-61.
33. Chew, EY et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010. 363(3): p. 233-44.
34. Cariou, B, Zaïr, Y, Staels, B, Bruckert, E. Effects of the new dual PPARα/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care, 2011 (in press).
35. Hanf, R, Hum, DW, Staels, B. GFT505 Efficacy and Safety in Healthy Volunteers and Patients Suffering from Atherogenic Dyslipidemia. American Diabetes Association, 70th Scientific Session, 2010.
36. Buchwald, H et al. Bariatric surgery: a systematic review and meta-analysis. JAMA, 2004. 292(14): p. 1724-37.
37. Cummings, DE et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis, 2007. 3(2): p. 109-15.
38. Rubino, F et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg, 2006. 244(5): p. 741-9.
39. Caiazzo, R et al. Gastric bypass and glucose metabolism. Diabetes Metab, 2009. 35(6 Pt 2): p. 528-31.